Wuxi Apptec Co Unsp/Adr (WUXAY) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Wuxi Apptec Co., Ltd. Class A.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.118 Good morning, everyone. Welcome to the second half earnings call for Wuxi Apptech, 00:00:05.118 -- 00:00:10.166 the leading CDMO in China. My name is Lawrence Tam, China Healthcare Analyst at Morgan 00:00:10.166 -- 00:00:15.313 Stanley. First, I want to congratulate management for another strong 00:00:15.313 -- 00:00:21.021 quarter. This represents two consecutive quarters of beating consensus estimates. 00:00:21.021 -- 00:00:26.049 The company also reported a substantial rise in backlog, driven by its 00:00:26.049 -- 00:00:29.815 chemistry and, in particular, its ties business. 00:00:29.815 -- 00:00:34.940 Investors may have noticed from the company's PPT that Aptek raised its full-year 00:00:34.940 -- 00:00:40.506 revenue growth guidance by 2 to 3 percentage points to a range of 13 00:00:40.506 -- 00:00:42.148 to 17% 00:00:42.148 -- 00:00:47.233 full-year revenue growth. With that, let me introduce Aptek's management team who 00:00:47.233 -- 00:00:50.136 will be presenting today. First, 00:00:50.136 -- 00:00:53.720 we have Mr. Mingzhang Chen, co-CEO, 00:00:53.720 -- 00:00:59.347 and Mr. Steve Yang, co-CEO, Ms. Florence Shi, CFO, 00:00:59.347 -- 00:01:04.615 Mr. Howard Wu, General Counsel, Ms. Min Han, the 00:01:04.615 -- 00:01:10.184 Board Secretary, and Ms. Reija Tang, IR Director. 00:01:10.184 -- 00:01:14.628 Now, let me turn it over to Reija. Please, Reija. 00:01:16.053 -- 00:01:20.680 Okay. Thank you, Lawrence. And thank you to all the investors and analysts for joining 00:01:20.680 -- 00:01:25.688 today's earnings call. We're sharing our 2025 interim results presentation, which you 00:01:25.688 -- 00:01:28.085 can also find on our website. 00:01:28.085 -- 00:01:31.291 During today's call, we will make forward-looking stateme...